• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

ODI Pharma

2.44 SEK

-8.96 %

Less than 1K followers

ODI

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-8.96 %
-37.44 %
-40.78 %
-43.52 %
-32.22 %
+11.93 %
-46.39 %
-45.68 %
-78.27 %

ODI Pharma is a producer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are made through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. Operations are found within the European market, with the headquarters in Stockholm.

Read more
Market cap
44.73M SEK
Turnover
48.93K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8.
2026

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/2/2026, 2:12 PM

ODI Pharma completes final loan repayment and becomes debt-free

ODI Pharma
Press release5/28/2026, 4:00 PM

ODI Pharma: Publication of interim report Q3 2025/2026

ODI Pharma
Press release2/26/2026, 7:00 AM

ODI Pharma: Publication of half-year report 2025/2026

ODI Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release12/29/2025, 2:30 PM

ODI Pharma issues a reverse profit warning following improved revenue development

ODI Pharma
Press release12/5/2025, 5:45 PM

Notice to Annual General Meeting in ODI Pharma AB (publ)

ODI Pharma
Press release11/27/2025, 3:35 PM

ODI Pharma: Publication of interim report Q1 2025/2026

ODI Pharma
Press release11/24/2025, 2:15 PM

ODI Pharma demonstrates clear operational progress and improved commercial outlook

ODI Pharma
Press release11/21/2025, 6:00 PM

ODI Pharma AB publishes the annual report for the fiscal year 2024/2025

ODI Pharma
Press release10/31/2025, 11:10 AM

Notice to Annual General Meeting in ODI Pharma AB (publ)

ODI Pharma
Press release8/29/2025, 9:22 AM

ODI Pharma publishes financial calendar for 2025

ODI Pharma
Press release8/28/2025, 4:10 PM

ODI Pharma: Publication of year-end report Q4 2024/2025

ODI Pharma
Press release6/26/2025, 1:55 PM

ODI Pharma: Report from the Extraordinary General Meeting

ODI Pharma
Regulatory press release6/9/2025, 6:15 PM

ODI Pharma proposes directed share issue of approximately SEK 2.0 million

ODI Pharma
Press release5/29/2025, 12:00 PM

ODI Pharma: Publication of interim report Q3 2024/2025

ODI Pharma